NEWSROOM | Galderma

TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously

A common purpose

Centering patient needs: Dr. Shridharani's shared values with Galderma

Results from Galderma’s phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines

Our culture

Galderma reports record net sales of over 3 B USD for the first nine months of 2023 with strong growth momentum across all product categories

Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab’s rapid onset of action in patients with prurigo nodularis

Providing optimal care for optimal results with Cetaphil

Galderma unveils bold ambition in neuromodulation at Liquid Live event

Galderma @ EADV 2023: phase III trials demonstrate nemolizumab’s efficacy and rapid onset of action in atopic dermatitis and prurigo nodularis

EADV 2023: Galderma's scientific presentations

EADV 2023: Galderma to present new data showcasing its continued leadership in dermatology